Drugs News and Research

RSS

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

Berg, a Boston-based biopharmaceutical company, and the University of Miami Leonard M. Miller School of Medicine are extending its collaboration to battle cardiac dysfunction and heart failure. According to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030.

23 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease.

21 Aug 2015

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Every year, more strains of bacteria develop resistance to the antibiotics we use to treat deadly infections. At The Scripps Research Institute (TSRI) scientists have been working to develop new forms of these drugs, including an antibiotic called arylomycin—but tests have shown that it is possible for bacteria to become resistant to arylomycin, too.

20 Aug 2015

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S. patent no. 9,107,823 ('823 Patent) covering novel topical foam formulations that include dimethyl sulfoxide (DMSO) together with certain drug actives.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events.

20 Aug 2015

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

20 Aug 2015

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

20 Aug 2015

New iPS cell model provides clear drug target for treatment of DMD

Duchenne muscular dystrophy (DMD) is a muscular disease that shows symptoms in early childhood and causes progressive atrophy and eventual death. There is little in terms of treatment, partly because of poor understanding of how DMD develops, although it is known that abnormal expression of the protein dystrophin is at fault.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Discovery provides new insights into how asthma may be caused

Researchers from the University of Leicester and University Hospitals of Leicester NHS Trust, working with the National Institute of Allergy and Infectious Diseases and Genentech, have discovered new insights into how asthma may be caused, by identifying three distinct groups of asthma patients characterised by the activity of different genes in an individual's airways.

20 Aug 2015

New genome-wide association study sheds light on the underlying biology of polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) has been passed down in many families for generations -- causing reproductive and metabolic health problems for millions of women around the world. Yet, its cause remains unknown despite more than 80 years of research since the disorder was first described in 1935.

20 Aug 2015

Programme to tackle superbugs announced by charity

Antibiotic Research UK announced at its Annual General meeting its first research programme to tackle antibiotic resistant bacteria (superbugs).

20 Aug 2015

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Drugs News and Research

Berg and University of Miami extend partnership to battle cardiac dysfunction, heart failure

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

60P to commence Phase II clinical trial among dengue fever patients

Surprising mechanism behind antibiotic resistant bacteria uncovered by TSRI scientists

Nuvo Research granted U.S. patent for novel topical foam formulations that use DMSO to enhance drug delivery

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

New iPS cell model provides clear drug target for treatment of DMD

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Discovery provides new insights into how asthma may be caused

New genome-wide association study sheds light on the underlying biology of polycystic ovary syndrome

Programme to tackle superbugs announced by charity

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News